BA3361, a CAB-ADC targeting Nectin-4, showed good in vitro and in vivo efficacy data demonstrating cytotoxicity against human Nectin-4-expressing tumor cell lines and tumor regression in xenograft models using the vedotin linker (AACR 2020, Poster #4560). To eliminate vedotin linker-related off-...
Henlius’ phase 3 clinical study of its innovative anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) was published as poster presentation...
February 9, 2022:Late-Breaking and Clinical Trials Abstract Status Notifications Sent/最新数据与临床试验摘要状态通知发送 February 11, 2022:Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition February 11, 2022:Membership Application Deadline for Advance Registration February 18, ...
February 9, 2022:Late-Breaking and Clinical Trials Abstract Status Notifications Sent/最新数据与临床试验摘要状态通知发送 February 11, 2022:Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition February 11, 2022:Membership Application Deadline for Advance Registration February 18, ...
2024年4月10日,复宏汉霖(2696.HK)宣布,公司首个创新型单抗H药 汉斯状®(斯鲁利单抗)一线治疗广泛期小细胞肺癌(ES-SCLC)的国际多中心III期临床试验ASTRUM-005的探索性生物标志物分析数据在2024年美国癌症协会年会(AACR 2024)上以壁报形式展示,该研究的主要研究者为吉林省肿瘤医院程颖教授。
◆ 下次会议:2023年第7届CRI-ENCI-AACR国际癌症免疫治疗大会(CICON2023) ◆ 会议简介: 2022年第6届CRI-ENCI-AACR国际癌症免疫治疗大会将于2022年9月28日至10月1日在美国纽约举行,会议议题涵盖癌症免疫学和免疫治疗的所有研究领域。该会议于2015年启动,由癌症研究所(CRI)、欧洲癌症免疫治疗网络(ENCI)和美国癌症研...
Study: Extend Quality Assessment to Phase I Abstracts: Poster Study at EORTC-NCI-AACR Meeting Gives Suggested Guidelinesdoi:10.1097/01.COT.0000343990.74265.d4An abstract is unavailable.Lindsey, HeatherOncology Times
The“full access”virtual Symposium registration includes access to all live broadcast scientific sessions including the Opening Ceremony and on-demand sessions, along with the virtual exhibition and online poster areas. It also includes exclusive access to the webcasts for 3 months after the Symposiu...
2024年4月10日,复宏汉霖(2696.HK)宣布,公司首个创新型单抗H药 汉斯状(斯鲁利单抗)一线治疗广泛期小细胞肺癌(ES-SCLC)的国际多中心III期临床试验ASTRUM-005的探索性生物标志物分析数据在2024年美国癌症协会年会(AACR 2024)上以壁报形式展示,该研究的主要研究者为吉林省肿瘤医院程颖教授。